We report the case of the development of two different stages of the same clonal disorder in two patients sharing the same bone marrow due to a previous bone marrow allotransplant. The transplanted patient developed severe aplasia with myeloid blasts, different from those of the previously cured leukemia. Chimerism evaluated by microsatellite analyses confirmed a full donor phenotype. At the same time, the donor of the bone marrow transplantation developed a refractory anemia with excess blasts. We speculate on the presence of an undetectable pre-existing pathological clone in the transplanted bone marrow, which have evolved in the two patients. Myelodysplastic syndrome (MDS) is a clonal disorder characterized by a cellular marrow with impaired morphology and maturation (dysmyelopoiesis) and peripheral blood cytopenias, resulting from ineffective blood cell production.
Myelodysplastic syndrome (MDS) is a clonal disorder characterized by a cellular marrow with impaired morphology and maturation (dysmyelopoiesis) and peripheral blood cytopenias, resulting from ineffective blood cell production. 1 Cytogenetic studies of the bone marrow cells indicate mutations into clonal cell lines, with chromosomal abnormalities in up to 79% of cases, in different series. About 60-70% of cases are classified as primary MDS and even if weak evidence supports genetic predisposition, familial incidence has been described. 2, 3 As these cell lines continue to divide and provide the marrow with dysplastic cells, bone marrow dysfunction becomes apparent. As the disease progresses, additional gene mutations may occur leading to the proliferation of leukemic cells. Between the MDSs, refractory anemia with excess blasts (RAEB) is considered to be a preleukemic state since the large majority of patients affected by RAEB soon develop acute leukemia. The evolution from a nonaggressive disease to a dramatically evolving leukemia is often evoked to explain why neoplastic transformation could be considered as a multistep phenomenon. It is unclear whether subsequent mutations are caused by insults from the external environment, develop as a result of an intrinsic instability of the genome or derive from an inefficient repair system. 1, 4 A different, but not exclusive, hypothesis can be based on the host's status. It is possible that in the MDSs, a still efficient immune system controls disease progression. Conversely, when for largely unknown reasons the disease overcomes the host's defences, it will progress independent of the acquisition of additional mutations.
2,5 Independent of these hypotheses, the disease progression is considered to develop randomly, and this may explain the extremely variable time span between the initial diagnosis and the final evolution of the disease.
A 37-year-old woman with Pseudomonas aeruginosa sepsis, lobar pneumonia and marrow aplasia came to our attention. The history revealed an acute M4 leukemia diagnosed 19 years earlier. At diagnosis, she presented white cell count 39.7 Â 10 9 /l (96% of blastic cells), hemoglobin 8.1 g/dl and platelet count 168 Â 10 9 /l; tonsillar hypertrophy was also present. She had been treated by chemotherapy with an induction course of daunorubicin, Ara-C and VP-16, followed by a consolidation course and maintenance therapy, with the same drugs. After 6 months, allogeneic bone marrow transplantation had been performed (conditioned with edatrexate, 120 mg/kg, and total body irradiation; cyclosporine, 3 mg/kg, was used for graftversus-host disease prevention, for a period of 4 years). The patient had enjoyed good health until 2 years earlier, when moderate pancytopenia (white cell count 3.1 Â 10 9 /l, 14% neutrophils, hemoglobin 11.5 g/dl, medium globular volume 112 fl and platelet count 115 Â 10 9 /l) appeared. Blood counts quickly worsened, she became transfusion dependent and was treated by 1 mg/kg/day 6-methylprednisolone. Finally, she was admitted to our hospital with severe pneumonia. On admission, the patient's blood counts revealed: white cell count 0.25 Â 10 9 /l (differential: 7% neutrophils, 87% lymphocytes, 6% monocytes), hemoglobin 6.3 g/dl and platelet count 2.3 Â 10 9 /l. The morphological examination of the peripheral blood smears did not reveal the presence of any blasts and confirmed the pancytopenia, while bone marrow aspirate showed poor cellularity of the samples with few small erythroblastic islets, megakaryocytes, some plasma cells and undifferentiated type I blasts (Figure 1a and b) . Bone marrow cytofluorimetric analysis showed 20% of the cells
þ ) blast cells were identified in a specific gate. The search for Flt-3 mutations by polymerase chain reaction and conventional cytogenetic analysis were both negative. Chimerism evaluated on whole bone marrow by microsatellite analyses confirmed a full donor phenotype (Figure 2) .
The patient died after several days due to the documented P. aeruginosa sepsis. At the time of pancytopenia onset (year 2000), the donor, a 40-year-old sister of the patient, was found to have a mild leukopenia (2.8 Â 10 9 /l white blood cells) with neutropenia. When the diagnosis of aplastic leukemia was performed in the patient, the donor underwent peripheral blood smear and bone marrow examination. Blood counts revealed macrocytic anemia with peripheral blood cytopenia (white cell count 2.9 Â 10 9 /l; differential: 73% neutrophils, 22% lymphocytes, 2% monocytes); no blasts were detectable. The microscopic evaluation of the bone marrow showed a hypercellular marrow, myeloid maturative hiatus with an increased number of type I myeloid blasts (15%) characterized by increased nuclear/cytoplasm ratio, reticular chromatin, inconspicuous nucleoli and clear hypogranular cytoplasm (Figure 1c and d) . Dyserythropoiesis and reduction of the megakaryocytic lineage with hypolobulated cells were detected. Cytofluorimetric analysis showed 52% of the Myeloid blasts (CD33 þ , CD13 þ ) were identified in a specific gate. Flt-3 mutations and the cytogenetic analysis were both negative. She has submitted to a frequent followup and, after 5 months, blast number has increased to 20%, with an evident increment of the dysplastic features. Interestingly, blasts from the two patients appear to be morphologically and phenotypically identical.
The onset of myelodysplastic disease in two members of the same family, one of whom had been previously cured for a different myeloid leukemia, suggests the presence of intrinsic damage in the genome, inducing or facilitating the development of hematological neoplastic disorders. Moreover, the contemporaneous onset of the same disease in two different hosts 18 years after bone marrow transplantation strongly confirms the presence of intrinsic damage in donor's stem cells. Besides the morphological and phenotypic identity of blasts, the donor origin of neoplastic cells is confirmed by chimerism analysis. The two sisters led independent lives, residing in different areas, with different jobs and unrelated lifestyles. It appears unlikely that the same external etiological agent had induced a neoplastic damage, after transplantation was performed. Conversely, the presence of an undetectable pre-existing pathological clone appears to be a reasonable hypothesis. It is difficult to determine whether myelodysplastic cells had already been present 18 years earlier in the donor or if, at that time, certain intrinsically damaged cells were able to induce or progress to the disease. In the latter case, we must assume that the same pre-existing alterations necessarily evolved into a neoplastic disease, for instance, by inducing further abnormalities, independent of additional external noxae which are unlikely to have contemporaneously occurred in two independent hosts. The effects of these abnormalities appeared differently in the two sisters due to their different clinical conditions. This observation confirms the host's role in controlling the severity and rapidity of disease progression. It is not surprising that the contemporaneous onset of cytopenia had evolved in a short span of time in the transplanted patient, where the immune reconstitution is supposed to be incomplete, 5 while in the donor the disease appears to be relatively stable, with a fairly constant blast percentage over 6 months, confirming the possible role of an immunological control. Consequently, we can hypothesize the presence of an undetectable pre-existing pathological clone in the transplanted bone marrow, which due to an unknown intracellular clock had evolved at the same time in the two different patients.
